MAAT — Maat Pharma SA Share News
0.000.00%
Last trade - 00:00- €18.38m
- €24.99m
- €4.52m
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026
Brief: Maat Pharma Says Maat033 Shows Favorable Safety Profile And Tolerability
Brief: Euronext: Quarterly Review Of CAC Family
Brief: MaaT Pharma Signs Licensing, Commercial Supply Agreement With Clinigen for Xervyteg Medicine
Brief: Maat Pharma Announces Xervyteg's Phase 3 Dedicated Trial Launch In U.S Is Expected In 2026
Brief: MaaT Pharma Announces Positive Outcomes From Final DSMB Meeting For Phase 3 Clinical Trial Evaluating MaaT013 In Acute Graft-Versus-Host Disease
Brief: Maat Pharma Announces Positive Topline Results From Phase 3 Ares Study
Brief: Maat Pharma Says MaaT033 Shows Good Safety Profile And Tolerability In ALS Patients
Brief: MaaT Pharma: Positive Results With MAAT013, Insights On Ongoing Phase 2B Trial
French and Benelux stocks-Factors to watch
Brief: Maat Pharma Receives State Funding For The Clinical Development Of Maat033
Brief: Maat Pharma Q3 Revenues At 0.4 Million Euros
Brief: Maat Pharma: 1st Patient Dosed In Phase 2B Randomized Clinical Trial Evaluating MaaT033
Brief: Maat Pharma To Present Preclinical Data On AI-Generated Immunotherapy Product
Brief: Maat Pharma Announces Positive Outcome Following Dsmb Review Reinforcing Confidence In Phase 3 On-Going Trial In Acute Graft-Versus-Host Disease With Maat013
Brief: Maat Pharma Increases Resources Allocated To Liquidity Contract With Kepler Cheuvreux